市場調查報告書

胰島素輸液幫浦的全球市場:成長率,趨勢及預測(2019年∼2024年)

Insulin Infusion Pumps Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 391359
出版日期 內容資訊 英文 100 Pages
商品交期: 2-3個工作天內
價格
胰島素輸液幫浦的全球市場:成長率,趨勢及預測(2019年∼2024年) Insulin Infusion Pumps Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年03月01日內容資訊: 英文 100 Pages
簡介

全球胰島素輸液幫浦市場在預測期間內,預計將以7.51%的年複合成長率成長。胰島素輸液幫浦,用作替代傳統每天的注射系統或胰島素筆針。

本報告提供全球胰島素輸液幫浦市場調查,整體市場趨勢,各產品、地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等資訊總括性彙整。

目錄

第1章 簡介

  • 調查的成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
  • 市場阻礙因素
  • 波特的五力分析
    • 賣主談判力
    • 買方議價能力
    • 新加入廠商的威脅
    • 替代產品及服務的威脅
    • 競爭的激烈程度

第5章 市場細分化

  • 各產品(以金額、數量為準,2012年∼2024)
    • 胰島素幫浦
    • 輸液套組
    • 藥液容器
  • 地區
    • 北美
    • 亞太地區
    • 歐洲
    • 南美
    • 中東、非洲

第6章 市場指標

  • 第一型糖尿病人口(2012年∼2024年)
  • 第二型糖尿病人口(2012年∼2024年)

第7章 競爭情形

  • 企業簡介
    • Medtronic
    • Medtronic
    • Insulet
    • Roche
    • Animas
    • Tandem
    • Ypsomed
    • Cellnovo
  • 企業佔有率分析
    • Roche
    • Animas
    • Medtronic
    • 其他

第8章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 54014

Market Overview

The global insulin infusion pump market is set to witness a CAGR of 7.51% during the forecast period. Insulin infusion pumps work as an alternative to the traditional system of daily injections or an insulin pen.

Insulin infusion pumps reduce the large swings in blood glucose level, lessen pain, and deliver more accurately than injections. The scheduling of meal timings is not required when using pumps.

This makes infusion pumps more user-friendly for patients. Insulin therapy is also known as continuous subcutaneous insulin infusion (CSII). It is an efficient and flexible method of insulin delivery.

The insulin pump has evolved and is more reliable than it was previously. CSII technology has witnessed numerous technological advancements, like the integration of continuous glucose monitoring with the pump. Now, insulin pumps can control the algorithm that automatically delivers the insulin, after analyzing the blood glucose reading

Scope of the Report

The insulin market is segmented into the device, infusion set, and reservoir. The report is also segmented into five regions: North America, Asia-Pacific, Europe, Middle East & Africa, and Latin America.

Key Market Trends - The Insulin Pump Market is Growing with the CAGR of 7% in the Forecast Period

Owing to the rising rate of obesity, growing genetic factors for type 2 diabetes, and the increasing number of type 1 diabetes patients, it is likely that the insulin infusion pump market will continue to grow.

Insulin pump use is high among the type 1 population. It is also growing in type 2 patients. The ratio of children to adult, or type 1 to type 2, patient's usage of insulin pumps varies across countries.

North America Holds the Highest Market Share

North America holds the highest market share in the insulin pump market and is also expected to grow with the highest CAGR, of 9.05% in the forecast period, because of the favorable reimbursement policy. Although the pump and its supplies (tubing, insulin cartridges, and infusion sets) continue to be expensive, insurance coverage has improved considerably over the years.

Competitive Landscape

Animas had to exit the insulin pump market, as the company has admitted that rising competition was the reason for them to leave the market.

Medtronic is the market leader and is expected to maintain its position during the forecast period.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product (Value and Volume 2012-2024)
    • 5.1.1 Insulin Pumps
    • 5.1.2 Infusion Sets
    • 5.1.3 Reservoirs
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States (Value and Volume 2012-2024)
      • 5.2.1.1.1 By Insulin Pump Devices
      • 5.2.1.1.2 By Infusion Sets
      • 5.2.1.1.3 By Reservoirs
      • 5.2.1.2 Canada (Value and Volume 2012-2024)
      • 5.2.1.2.1 By Insulin Pump Devices
      • 5.2.1.2.2 By Infusion Sets
      • 5.2.1.2.3 By Reservoirs
      • 5.2.1.3 Rest of North America (Value and Volume 2012-2024)
      • 5.2.1.3.1 By Insulin Pump Devices
      • 5.2.1.3.2 By Infusion Sets
      • 5.2.1.3.3 By Reservoirs
    • 5.2.2 Asia-Pacific
      • 5.2.2.1 Japan (Value and Volume 2012-2024)
      • 5.2.2.1.1 By Insulin Pump Devices
      • 5.2.2.1.2 By Infusion Sets
      • 5.2.2.1.3 By Reservoirs
      • 5.2.2.2 South Korea (Value and Volume 2012-2024)
      • 5.2.2.2.1 By Insulin Pump Devices
      • 5.2.2.2.2 By Infusion Sets
      • 5.2.2.2.3 By Reservoirs
      • 5.2.2.3 China (Value and Volume 2012-2024)
      • 5.2.2.3.1 By Insulin Pump Devices
      • 5.2.2.3.2 By Infusion Sets
      • 5.2.2.3.3 By Reservoirs
      • 5.2.2.4 India (Value and Volume 2012-2024)
      • 5.2.2.4.1 By Insulin Pump Devices
      • 5.2.2.4.2 By Infusion Sets
      • 5.2.2.4.3 By Reservoirs
      • 5.2.2.5 Australia (Value and Volume 2012-2024)
      • 5.2.2.5.1 By Insulin Pump Devices
      • 5.2.2.5.2 By Infusion Sets
      • 5.2.2.5.3 By Reservoirs
      • 5.2.2.6 Vietnam (Value and Volume 2012-2024)
      • 5.2.2.6.1 By Insulin Pump Devices
      • 5.2.2.6.2 By Infusion Sets
      • 5.2.2.6.3 By Reservoirs
      • 5.2.2.7 Malaysia (Value and Volume 2012-2024)
      • 5.2.2.7.1 By Insulin Pump Devices
      • 5.2.2.7.2 By Infusion Sets
      • 5.2.2.7.3 By Reservoirs
      • 5.2.2.8 Indonesia (Value and Volume 2012-2024)
      • 5.2.2.8.1 By Insulin Pump Devices
      • 5.2.2.8.2 By Infusion Sets
      • 5.2.2.8.3 By Reservoirs
      • 5.2.2.9 Philippines (Value and Volume 2012-2024)
      • 5.2.2.9.1 By Insulin Pump Devices
      • 5.2.2.9.2 By Infusion Sets
      • 5.2.2.9.3 By Reservoirs
      • 5.2.2.10 Thailand (Value and Volume 2012-2024)
      • 5.2.2.10.1 By Insulin Pump Devices
      • 5.2.2.10.2 By Infusion Sets
      • 5.2.2.10.3 By Reservoirs
      • 5.2.2.11 Rest of Asia-Pacific (Value and Volume 2012-2024)
      • 5.2.2.11.1 By Insulin Pump Devices
      • 5.2.2.11.2 By Infusion Sets
      • 5.2.2.11.3 By Reservoirs
    • 5.2.3 Europe
      • 5.2.3.1 United Kingdom (Value and Volume 2012-2024)
      • 5.2.3.1.1 By Insulin Pump Devices
      • 5.2.3.1.2 By Infusion Sets
      • 5.2.3.1.3 By Reservoirs
      • 5.2.3.2 France (Value and Volume 2012-2024)
      • 5.2.3.2.1 By Insulin Pump Devices
      • 5.2.3.2.2 By Infusion Sets
      • 5.2.3.2.3 By Reservoirs
      • 5.2.3.3 Germany (Value and Volume 2012-2024)
      • 5.2.3.3.1 By Insulin Pump Devices
      • 5.2.3.3.2 By Infusion Sets
      • 5.2.3.3.3 By Reservoirs
      • 5.2.3.4 Italy (Value and Volume 2012-2024)
      • 5.2.3.4.1 By Insulin Pump Devices
      • 5.2.3.4.2 By Infusion Sets
      • 5.2.3.4.3 By Reservoirs
      • 5.2.3.5 Spain (Value and Volume 2012-2024)
      • 5.2.3.5.1 By Insulin Pump Devices
      • 5.2.3.5.2 By Infusion Sets
      • 5.2.3.5.3 By Reservoirs
      • 5.2.3.6 Russia (Value and Volume 2012-2024)
      • 5.2.3.6.1 By Insulin Pump Devices
      • 5.2.3.6.2 By Infusion Sets
      • 5.2.3.6.3 By Reservoirs
      • 5.2.3.7 Rest of Europe (Value and Volume 2012-2024)
      • 5.2.3.7.1 By Insulin Pump Devices
      • 5.2.3.7.2 By Infusion Sets
      • 5.2.3.7.3 By Reservoirs
    • 5.2.4 Latin America
      • 5.2.4.1 Mexico (Value and Volume 2012-2024)
      • 5.2.4.1.1 By Insulin Pump Devices
      • 5.2.4.1.2 By Infusion Sets
      • 5.2.4.1.3 By Reservoirs
      • 5.2.4.2 Brazil (Value and Volume 2012-2024)
      • 5.2.4.2.1 By Insulin Pump Devices
      • 5.2.4.2.2 By Infusion Sets
      • 5.2.4.2.3 By Reservoirs
      • 5.2.4.3 Rest of Latin America (Value and Volume 2012-2024)
      • 5.2.4.3.1 By Insulin Pump Devices
      • 5.2.4.3.2 By Infusion Sets
      • 5.2.4.3.3 By Reservoirs
    • 5.2.5 Middle East & Africa
      • 5.2.5.1 Saudi Arabia (Value and Volume 2012-2024)
      • 5.2.5.1.1 By Insulin Pump Devices
      • 5.2.5.1.2 By Infusion Sets
      • 5.2.5.1.3 By Reservoirs
      • 5.2.5.2 Iran (Value and Volume 2012-2024)
      • 5.2.5.2.1 By Insulin Pump Devices
      • 5.2.5.2.2 By Infusion Sets
      • 5.2.5.2.3 By Reservoirs
      • 5.2.5.3 Egypt (Value and Volume 2012-2024)
      • 5.2.5.3.1 By Insulin Pump Devices
      • 5.2.5.3.2 By Infusion Sets
      • 5.2.5.3.3 By Reservoirs
      • 5.2.5.4 Oman (Value and Volume 2012-2024)
      • 5.2.5.4.1 By Insulin Pump Devices
      • 5.2.5.4.2 By Infusion Sets
      • 5.2.5.4.3 By Reservoirs
      • 5.2.5.5 South Africa (Value and Volume 2012-2024)
      • 5.2.5.5.1 By Insulin Pump Devices
      • 5.2.5.5.2 By Infusion Sets
      • 5.2.5.5.3 By Reservoirs
      • 5.2.5.6 Rest of Middle East & Africa (Value and Volume 2012-2024)
      • 5.2.5.6.1 By Insulin Pump Devices
      • 5.2.5.6.2 By Infusion Sets
      • 5.2.5.6.3 By Reservoirs

6 MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population (2012-2024)
  • 6.2 Type-2 Diabetes Population (2012-2024)

7 COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Medtronic
    • 7.1.2 Insulet
    • 7.1.3 Roche
    • 7.1.4 Animas
    • 7.1.5 Tandem
    • 7.1.6 Ypsomed
    • 7.1.7 Cellnovo
  • 7.2 COMPANY SHARE ANALYSIS
    • 7.2.1 Roche
    • 7.2.2 Animas
    • 7.2.3 Medtronic
    • 7.2.4 Others

8 MARKET OPPORTUNITIES AND FUTURE TRENDS